Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 3/20 | 0.33 |
| ▸ | CDK8 | P49336 | 3/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.33 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1082611 | 0.80 | NOTUM (0.65) | NOTUMPOLBALDH1A1CYP1A2CCNC | |
| SCHEMBL1504482 | 0.76 | ALDH1A1 (0.42) | POLBALDH1A1GDAMAPTMEN1 | |
| SCHEMBL7427038 | 0.75 | NOTUM (0.44) | NOTUMPOLBALDH1A1CYP1A2CCNC | |
| SCHEMBL19438592 | 0.75 | ALDH1A1 (0.50) | ALDH1A1CYP1A2MAPTMEN1LMNA | |
| SCHEMBL24809450 | 0.70 | NOTUM (0.39) | NOTUMPOLBALDH1A1CYP1A2MAPT | |
| SCHEMBL10057754 | 0.70 | NOTUM (0.39) | NOTUMPOLBCYP1A2MAPT | |
| SCHEMBL7475587 | 0.70 | CCNC (0.42) | NOTUMALDH1A1CCNCCDK8SLC9A1 | |
| SCHEMBL20157257 | 0.67 | CCNC (0.51) | NOTUMALDH1A1CCNCCDK8SLC9A1 | |
| SCHEMBL31307651 | 0.66 | POLB (0.48) | POLBALDH1A1CYP1A2MAPTMEN1 | |
| SCHEMBL12663437 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021239727-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-12-02 | — | — | WO | disclosed |
| EP-3915990-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | Centre National de la Recherche Scientifique (FR) | 2021-12-01 | — | — | EP | disclosed |
| EP-2084130-B1 | PROCESS FOR PREPARING 5-ALKYL-7H-PYRROLO[2,3-D]PYRIMIDINE-2-OLS | LEXICON PHARMACEUTICALS INC (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2084130-B1 | PROCESS FOR PREPARING 5-ALKYL-7H-PYRROLO[2,3-D]PYRIMIDINE-2-OLS | LEXICON PHARMACEUTICALS INC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-7951941-B2 | Process for preparing 5-alkyl-7H-pyrrolo[2,3-d] pyrimindine-2-ols | LEXICON PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951941-B2 | Process for preparing 5-alkyl-7H-pyrrolo[2,3-d] pyrimindine-2-ols | LEXICON PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951941-B2 | Process for preparing 5-alkyl-7H-pyrrolo[2,3-d] pyrimindine-2-ols | LEXICON PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-2084130-A1 | PROCESS FOR PREPARING 5-ALKYL-7H-PYRROLO[2,3-D]PYRIMIDINE-2-OLS | Lexicon Pharmaceuticals, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008051887-A1 | PROCESS FOR PREPARING 5-ALKYL-7H-PYRROLO[2,3-D]PYRIMIDINE-2-OLS | LEXICON PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051887-A1 | PROCESS FOR PREPARING 5-ALKYL-7H-PYRROLO[2,3-D]PYRIMIDINE-2-OLS | LEXICON PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20080097098-A1 | PROCESS FOR PREPARING 5-ALKYL-7H-PYRROLO[2,3-d] PYRIMINDINE-2-OLS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-04-24 | — | — | US | disclosed |
| US-20080097098-A1 | PROCESS FOR PREPARING 5-ALKYL-7H-PYRROLO[2,3-d] PYRIMINDINE-2-OLS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-04-24 | — | — | US | disclosed |
| US-20080097098-A1 | PROCESS FOR PREPARING 5-ALKYL-7H-PYRROLO[2,3-d] PYRIMINDINE-2-OLS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097098-A1 | PROCESS FOR PREPARING 5-ALKYL-7H-PYRROLO[2,3-d] PYRIMINDINE-2-OLS | THPO, DHPS, DPYD | NOTUM 3695/4885POLB 52/4885ALDH1A1 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.